Iovance Historical Balance Sheet

IOVA Stock

USD 10.59 1.69 13.76%

Trend analysis of Iovance Biotherapeutics balance sheet accounts such as Total Current Liabilities of 115.8 M or Total Stockholder Equity of 613.8 M provides information on Iovance Biotherapeutics' total assets, liabilities, and equity, which is the actual value of Iovance Biotherapeutics to its prevalent stockholders. By breaking down trends over time using Iovance Biotherapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Iovance Biotherapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Iovance Biotherapeutics is a good buy for the upcoming year.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.

About Iovance Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Iovance Biotherapeutics at a specified time, usually calculated after every quarter, six months, or one year. Iovance Biotherapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Iovance Biotherapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Iovance currently owns. An asset can also be divided into two categories, current and non-current.

Iovance Biotherapeutics Balance Sheet Chart

At present, Iovance Biotherapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 72.9 M, whereas Net Debt is forecasted to decline to (41 M).

Total Assets Other Current Liab Total Current Liabilities Property Plant And Equipment Net Inventory Accumulated Other Comprehensive Income

Add Fundamental

Total Assets

Total assets refers to the total amount of Iovance Biotherapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Iovance Biotherapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Iovance Biotherapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Iovance Biotherapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Accumulated Other Comprehensive Income

Gains and losses not included in net income that are recorded in shareholders' equity, reflecting changes in the value of assets or liabilities that are not realized.

Most accounts from Iovance Biotherapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Iovance Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.At present, Iovance Biotherapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 72.9 M, whereas Net Debt is forecasted to decline to (41 M).

	2021	2022	2023	2024 (projected)
Other Current Liabilities	56.8M	52.3M	69.4M	72.9M
Total Assets	777.3M	664.0M	780.4M	819.4M

Other Current Liab Total Assets

Iovance Biotherapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Intangible Assets	Accounts Payable	Non Currrent Assets Other	Short Long Term Debt Total	Net Tangible Assets	Current Deferred Revenue	Other Assets	Retained Earnings Total Equity
Total Assets		0.92	0.9	0.99	0.91	-0.06	-0.91	0.42	0.75	0.85	0.75	0.94	0.8	0.95	0.91	0.9	0.85	0.85	0.94	0.89	-0.23	0.86	0.99	-0.41	0.65	-0.96
Other Current Liab	0.92		0.99	0.87	0.98	0.02	-0.98	0.37	0.88	0.61	0.69	0.94	0.83	0.98	0.99	0.98	0.6	0.94	0.84	0.98	-0.29	0.89	0.86	-0.29	0.7	-0.94
Total Current Liabilities	0.9	0.99		0.85	0.98	0.05	-0.98	0.35	0.85	0.6	0.7	0.93	0.82	0.97	0.99	0.98	0.59	0.94	0.85	0.99	-0.33	0.89	0.84	-0.3	0.68	-0.95
Total Stockholder Equity	0.99	0.87	0.85		0.85	-0.09	-0.85	0.42	0.7	0.89	0.74	0.92	0.77	0.91	0.85	0.84	0.89	0.79	0.94	0.83	-0.19	0.82	1.0	-0.43	0.62	-0.93
Property Plant And Equipment Net	0.91	0.98	0.98	0.85		-0.01	-0.96	0.42	0.8	0.65	0.69	0.89	0.73	0.96	0.99	1.0	0.63	0.89	0.8	0.96	-0.4	0.95	0.85	-0.29	0.72	-0.96
Net Debt	-0.06	0.02	0.05	-0.09	-0.01		0.07	-0.89	0.19	-0.13	0.19	-0.12	-0.07	-0.08	0.04	-0.02	-0.16	0.1	0.07	0.06	0.43	-0.12	-0.09	0.36	0.14	0.06
Retained Earnings	-0.91	-0.98	-0.98	-0.85	-0.96	0.07		-0.44	-0.85	-0.58	-0.68	-0.96	-0.88	-0.99	-0.98	-0.97	-0.59	-0.94	-0.85	-0.98	0.36	-0.88	-0.85	0.33	-0.59	0.93
Cash	0.42	0.37	0.35	0.42	0.42	-0.89	-0.44		0.1	0.42	0.18	0.44	0.3	0.44	0.37	0.42	0.44	0.25	0.26	0.33	-0.63	0.55	0.42	-0.45	0.19	-0.47
Non Current Assets Total	0.75	0.88	0.85	0.7	0.8	0.19	-0.85	0.1		0.33	0.49	0.84	0.83	0.84	0.85	0.82	0.32	0.87	0.67	0.85	0.14	0.63	0.69	-0.22	0.58	-0.71
Cash And Short Term Investments	0.85	0.61	0.6	0.89	0.65	-0.13	-0.58	0.42	0.33		0.71	0.67	0.44	0.67	0.61	0.61	0.99	0.49	0.82	0.58	-0.25	0.71	0.9	-0.43	0.58	-0.8
Common Stock Total Equity	0.75	0.69	0.7	0.74	0.69	0.19	-0.68	0.18	0.49	0.71		0.65	0.57	0.7	0.7	0.68	0.72	0.75	0.79	0.68	-0.27	0.73	0.74	-0.02	0.51	-0.77
Common Stock Shares Outstanding	0.94	0.94	0.93	0.92	0.89	-0.12	-0.96	0.44	0.84	0.67	0.65		0.93	0.98	0.92	0.9	0.68	0.9	0.91	0.94	-0.21	0.8	0.91	-0.43	0.55	-0.92
Other Current Assets	0.8	0.83	0.82	0.77	0.73	-0.07	-0.88	0.3	0.83	0.44	0.57	0.93		0.88	0.8	0.75	0.48	0.88	0.82	0.83	-0.1	0.59	0.76	-0.34	0.28	-0.74
Other Stockholder Equity	0.95	0.98	0.97	0.91	0.96	-0.08	-0.99	0.44	0.84	0.67	0.7	0.98	0.88		0.98	0.96	0.67	0.94	0.89	0.97	-0.32	0.88	0.91	-0.37	0.61	-0.95
Total Liab	0.91	0.99	0.99	0.85	0.99	0.04	-0.98	0.37	0.85	0.61	0.7	0.92	0.8	0.98		0.99	0.6	0.93	0.83	0.98	-0.34	0.91	0.85	-0.29	0.68	-0.95
Property Plant And Equipment Gross	0.9	0.98	0.98	0.84	1.0	-0.02	-0.97	0.42	0.82	0.61	0.68	0.9	0.75	0.96	0.99		0.6	0.91	0.79	0.96	-0.4	0.94	0.84	-0.28	0.71	-0.95
Total Current Assets	0.85	0.6	0.59	0.89	0.63	-0.16	-0.59	0.44	0.32	0.99	0.72	0.68	0.48	0.67	0.6	0.6		0.49	0.83	0.57	-0.26	0.7	0.9	-0.43	0.5	-0.79
Common Stock	0.85	0.94	0.94	0.79	0.89	0.1	-0.94	0.25	0.87	0.49	0.75	0.9	0.88	0.94	0.93	0.91	0.49		0.83	0.92	-0.25	0.77	0.79	-0.14	0.53	-0.85
Intangible Assets	0.94	0.84	0.85	0.94	0.8	0.07	-0.85	0.26	0.67	0.82	0.79	0.91	0.82	0.89	0.83	0.79	0.83	0.83		0.85	-0.23	0.74	0.94	-0.36	0.53	-0.9
Accounts Payable	0.89	0.98	0.99	0.83	0.96	0.06	-0.98	0.33	0.85	0.58	0.68	0.94	0.83	0.97	0.98	0.96	0.57	0.92	0.85		-0.32	0.87	0.83	-0.33	0.69	-0.94
Non Currrent Assets Other	-0.23	-0.29	-0.33	-0.19	-0.4	0.43	0.36	-0.63	0.14	-0.25	-0.27	-0.21	-0.1	-0.32	-0.34	-0.4	-0.26	-0.25	-0.23	-0.32		-0.52	-0.2	0.07	-0.09	0.4
Short Long Term Debt Total	0.86	0.89	0.89	0.82	0.95	-0.12	-0.88	0.55	0.63	0.71	0.73	0.8	0.59	0.88	0.91	0.94	0.7	0.77	0.74	0.87	-0.52		0.82	-0.32	0.71	-0.94
Net Tangible Assets	0.99	0.86	0.84	1.0	0.85	-0.09	-0.85	0.42	0.69	0.9	0.74	0.91	0.76	0.91	0.85	0.84	0.9	0.79	0.94	0.83	-0.2	0.82		-0.45	0.62	-0.93
Current Deferred Revenue	-0.41	-0.29	-0.3	-0.43	-0.29	0.36	0.33	-0.45	-0.22	-0.43	-0.02	-0.43	-0.34	-0.37	-0.29	-0.28	-0.43	-0.14	-0.36	-0.33	0.07	-0.32	-0.45		-0.2	0.38
Other Assets	0.65	0.7	0.68	0.62	0.72	0.14	-0.59	0.19	0.58	0.58	0.51	0.55	0.28	0.61	0.68	0.71	0.5	0.53	0.53	0.69	-0.09	0.71	0.62	-0.2		-0.73
Retained Earnings Total Equity	-0.96	-0.94	-0.95	-0.93	-0.96	0.06	0.93	-0.47	-0.71	-0.8	-0.77	-0.92	-0.74	-0.95	-0.95	-0.95	-0.79	-0.85	-0.9	-0.94	0.4	-0.94	-0.93	0.38	-0.73

Click cells to compare fundamentals

Iovance Biotherapeutics Account Relationship Matchups

Iovance Biotherapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	344.7M	768.5M	777.3M	664.0M	780.4M	819.4M
Other Current Liab	16.3M	35.1M	56.8M	52.3M	69.4M	72.9M
Total Current Liabilities	39.1M	54.9M	89.2M	91.5M	110.3M	115.8M
Total Stockholder Equity	299.0M	656.5M	621.7M	499.6M	584.6M	613.8M
Property Plant And Equipment Net	19.2M	113.9M	169.9M	178.2M	176.5M	185.4M
Net Debt	(2.5M)	(15.7M)	(6.7M)	(147.3M)	(39.0M)	(41.0M)
Retained Earnings	(570.6M)	(830.2M)	(1.2B)	(1.6B)	(2.0B)	(1.9B)
Cash	14.0M	67.3M	78.2M	231.7M	114.9M	73.6M
Non Current Assets Total	32.1M	132.4M	269.4M	6.4M	472.5M	496.1M
Cash And Short Term Investments	307.1M	629.4M	596.0M	471.8M	279.9M	237.2M
Common Stock Shares Outstanding	124.3M	138.3M	153.4M	159.3M	235.1M	246.9M
Liabilities And Stockholders Equity	344.7M	768.5M	777.3M	664.0M	780.4M	819.4M
Other Current Assets	9.4M	6.7M	3.5M	7.3M	17.5M	18.3M
Other Stockholder Equity	869.4M	1.5B	1.8B	2.1B	2.6B	2.7B
Total Liab	45.7M	112.0M	155.7M	164.3M	195.7M	205.5M
Property Plant And Equipment Gross	19.2M	113.9M	178.6M	195.0M	204.5M	214.7M
Total Current Assets	312.5M	636.1M	508.0M	471.8M	307.8M	218.7M
Accounts Payable	15.6M	13.5M	27.4M	26.6M	33.1M	34.8M
Non Currrent Assets Other	7.4M	12.9M	7.9M	(178.2M)	270K	283.5K
Net Tangible Assets	299.0M	656.5M	621.7M	499.6M	574.6M	603.3M
Other Assets	8.9M	73.2M	777.3M	185.7M	213.6M	224.2M
Retained Earnings Total Equity	(372.8M)	(570.6M)	(830.2M)	(1.2B)	(1.1B)	(1.0B)
Short Term Investments	293.1M	562.1M	426.2M	240.1M	165.0M	188.1M
Capital Surpluse	839.0M	869.4M	1.5B	1.8B	2.1B	2.2B
Preferred Stock Total Equity	7K	6K	4K	3K	3.5K	3.2K
Accumulated Other Comprehensive Income	220K	19K	(601K)	(902K)	2.5M	2.7M
Property Plant Equipment	8.5M	59.2M	100.9M	178.2M	205.0M	215.2M
Non Current Liabilities Total	6.6M	57.1M	66.5M	84.4M	85.4M	89.7M
Net Invested Capital	299.0M	656.5M	622.7M	500.6M	585.6M	514.8M
Net Working Capital	277.4M	581.2M	418.8M	387.6M	197.5M	387.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
CRM	Salesforce
S	SentinelOne

When determining whether Iovance Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Iovance Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Iovance Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Iovance Biotherapeutics Stock:

How To Invest In Iovance

Details

Is Iovance Stock a good investment?

Details

What is Iovance Biotherapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.

You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.48)

Revenue Per Share

0.327

Quarterly Revenue Growth

123.851

Return On Assets

(0.33)

Return On Equity

(0.65)

The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Iovance Historical Balance Sheet

About Iovance Balance Sheet Analysis

Iovance Biotherapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Accumulated Other Comprehensive Income

Iovance Biotherapeutics balance sheet Correlations

Iovance Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Iovance Biotherapeutics balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 1.0	Total Stockholder Equity
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Stockholder Equity	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Assets
Total Current Liabilities	+ 0.99	Other Current Liab
Total Liab	+ 0.99	Other Current Liab

Other Stockholder Equity	- 0.99	Retained Earnings
Accounts Payable	- 0.98	Retained Earnings
Total Liab	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Total Current Liabilities
Retained Earnings	- 0.98	Other Current Liab
Property Plant And Equipment Gross	- 0.97	Retained Earnings